Earnings News - Candlesense

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigatio...

Are there any risks or uncertainties highlighted in the release that could affect the stock's volatility in the short term? What is the current cash position and projected runway, and does it raise concerns about dilution from future financing? Did the company issue any forward-looking statements regarding potential FDA milestones or trial readouts that could move the stock?

Symbol: TLSI

27 days ago

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boro...

Are there any disclosed risks or uncertainties (e.g., trial setbacks, regulatory challenges) that could impact future performance? How does AN2’s boron‑chemistry platform and Chagas program compare to competitors developing treatments for the same indications? What upcoming catalysts (e.g., data readouts, regulatory filings, conference presentations) could drive the stock in the next weeks?

Symbol: ANTX

27 days ago

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine an...

What impact might the sentiment score of 55 have on market perception and short‑term stock price movement? How does Stoke Therapeutics' valuation multiples (e.g., EV/Revenue, EV/EBITDA) compare to other RNA‑medicine peers? What are the key regulatory risks associated with zorevunersen's development program?

Symbol: STOK

27 days ago

BNY to Report Third Quarter 2025 Results on October 16, 2025

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- The Bank of New York Mellon Corporation ("BNY") (NYSE: BK), a global financial services company, will report financial results for the third quarter 2025 on ...

Are there any potential surprises or risks (e.g., credit loss provisions, litigation reserves) that could cause volatility after the results are announced? What is the expected market reaction to the earnings release and how should I position ahead of the report? Will the earnings call provide any insight into the bank's strategic initiatives, such as digital transformation or cost‑optimization measures?

Symbol: BK

27 days ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Second quarter 2025 revenues were $15.0 million

What potential catalysts (e.g., FDA approvals, product launches) could drive the stock price in the near term? Is there any insider trading activity or notable changes in institutional ownership following the release? What is the cash‑flow situation and balance‑sheet strength after the reported results?

Symbol: JMED

27 days ago

Read more globenewswire

CarParts.com Reports Second Quarter 2025 Results

TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ: PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and...

How will the Q2 2025 performance impact the technical outlook for PRTS, including key support and resistance levels on the chart? Are there any red‑flag items in the filing (e.g., higher than expected churn, inventory write‑downs, or credit losses) that warrant a risk assessment? What macro or industry trends (e.g., vehicle repair demand, parts supply chain disruptions) are reflected in the results, and how might they influence future quarters?

Symbol: PRTS

27 days ago

Smart Sand, Inc. Announces Second Quarter 2025 Results

2Q 2025 revenue of $85.8 million 2Q 2025 net income of $21.4 million which includes a $(21.7) million tax benefit 2Q 2025 cash flow used in operations of $(5.1) million 2Q 2025 contribution margin ...

What potential catalysts (e.g., contract wins, operational improvements) could move the stock in the near term? How does Smart Sand's performance stack up against peers in the hydraulic fracturing sand space? What is the company's capital allocation plan—will it address the negative cash flow through debt, equity, or asset sales?

Symbol: SMART

27 days ago

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025

What risks exist if the proof‑of‑mechanism data does not meet expectations or is delayed? How might the Phase 1 results impact analyst consensus estimates and target price for MZE? What market size and pricing assumptions are being used for PKU and CKD indications?

Symbol: MZE

27 days ago

Read more globenewswire

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, to...

Is there any indication of upcoming milestones that could trigger a catalyst-driven price movement? What are the potential risks related to trial enrollment rates and endpoint achievement for the autoimmune programs? How might the Q2 earnings results influence analyst coverage and consensus estimates for NKTX?

Symbol: NKTX

27 days ago

Read more globenewswire

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for ...

What is the market's perception of the long‑term growth prospects for SPRO based on the Q2 results and business update? Did the company announce any share repurchases, secondary offerings, or other capital structure actions that could affect liquidity or dilution? What potential catalysts or risk factors were highlighted that could drive short‑term volatility in the stock price?

Symbol: SPRO

27 days ago

Read more globenewswire